UNSPSC 51332303: Neflumozide

This classification denotes a dopamine antagonist with the molecular formula C22H23FN4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SU2C8RYO3O, chemically known as 1-(1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-piperidyl)-3h-benzimidazol-2(1h)-one hydrochloride but generally known as neflumozide hydrochloride, which bears US NIH Compound Identifier 55463. Most nations schedule neflumozide under HS 29349990 and SITC 51579. As of Q4 2014, NEFLUMOZIDE remains the US FDA Preferred Term for this commodity.

Neflumozide bears US NLM identifiers UMLS ID C2827279 and NCI Concept Code C83992. SMILES: C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC4=NOC5=C4C=CC(=C5)F.Cl.

UNSPSC 51332303 Neflumozide is a Commodity code that in practice does not align with the recent state and local opportunities posted under it. The code nominally describes a specific pharmaceutical compound, but recent solicitations tagged to this code actually cover naloxone procurement, direct-to-manufacturer prescription program design, and generic multi-source pharmaceutical supply agreements—none of which match neflumozide's narrow product scope. State and local buyers appear to be using this code as a catch-all for pharmaceutical and drug-management products and services rather than for neflumozide specifically. The issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon).

Recent opportunities show county and state-level health agencies sourcing naloxone and drug deactivation systems on an annual basis through IFB (Seminole County's IFB60459723LAS, response due July 26, 2023), state agencies exploring direct pharmaceutical contracting models through RFI (Texas HHS RFI HHS0017013, posted April 3, 2026), and regional cooperative purchasing groups managing statewide generic pharmaceutical and OTC product supply through RFP (Minnesota MMCAP's S1070000015802, due March 26, 2026, with effective date July 1, 2026). The geographic spread of recent activity spans Florida, Texas, Minnesota, and Oregon, with state-level health agencies and cooperative purchasing vehicles driving the most recent solicitations. Activity under this code remains sparse and poorly aligned with its nominal definition, making it an uncertain category for vendors seeking to track genuine pharmaceutical procurement demand.